Alzinova AB - Company & Market Research Reports

Alzinova AB is Swedish biotechnology enterprise engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company was founded in 2011 by the inventors of the AβCC peptide technology (patent pending) and MIVAC Development AB in close collaboration with the holding company at the University of Gothenburg in Sweden, GU Ventures AB. It is headquartered in Gothenburg, Sweden.

Alzheimer's Disease - Pipeline Review, H1 2018 - Product Thumbnail Image

Alzheimer's Disease - Pipeline Review, H1 2018

  • Report
  • 1203 Pages
From
Cognitive Impairment Disorders Drug Development Pipeline Review, 2018 - Product Thumbnail Image

Cognitive Impairment Disorders Drug Development Pipeline Review, 2018

  • Report
  • 376 Pages
From
Neurodegenerative Disorders Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Neurodegenerative Disorders Drug Development Pipeline Review, 2017

  • Report
  • 797 Pages
From
Active Immunization for Unconventional Indications Report - Product Thumbnail Image

Active Immunization for Unconventional Indications Report

  • Report
  • 166 Pages
From
Alzinova AB Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis - Product Thumbnail Image

Alzinova AB Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

  • Company Profile
  • 30 Pages
From
  • 5 Results (Page 1 of 1)
Loading Indicator
adroll